Elahere approved in EU as treatment for advanced ovarian cancer
AbbVie’s Elahere has been approved in the European Union as a treatment for adults with advanced, platinum-resistant ovarian cancer.| Rare Cancer News
Novo Nordisk’s $5.2 billion acquisition of Akero Therapeutics sits at the center of 2025’s hottest M&A space: MASH/metabolic disease. The deal, announced October 9, represents the largest of three major Fibroblast Growth Factor 21 (FGF21) analog acquisitions in five months. Across the broader landscape, 2025 pharma M&A activity reached approximately $70 billion in upfront consideration… The post 2025 pharma M&A surges to $70 billion in major deals appeared first on Drug Discovery and De...| Drug Discovery and Development
AbbVie (NYSE:ABBV) announced that it began construction for a $70 million expansion of its bioresearch center (ABC) in Worcester, Massachusetts. The ABC in Worcester serves as a center of excellence for biologics R&D and manufacturing. AbbVie said its latest expansion comes as part of a plan to invest more than $10 billion in the U.S.… The post AbbVie invests $70M in U.S. biologics manufacturing, R&D expansion appeared first on Pharmaceutical Processing World.| Pharmaceutical Processing World
AbbVie’s Elahere has been approved in the European Union as a treatment for adults with advanced, platinum-resistant ovarian cancer.| Rare Cancer News
